Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Feds open new GSK China bribery investigation

GlaxoSmithKline said in a securities filing Wednesday that the DOJ and SEC asked for information about third-party advisers the company hired in China during a corruption investigation there.

GSK said it is also responding to requests from the SFO for more information about the third parties.… Continue Reading

Tom Fox: Compliance in the Age of Mercantilism

What does the failure of the Kraft Heinz attempted hostile takeover of Unilever portend for the greater world of global anti-corruption enforcement specifically and compliance programs more generally?

As with most business issues during the new administration, things are in flux.… Continue Reading

GSK pays SEC $20 million to settle China FCPA violations

The Securities and Exchange Commission said Friday UK-based pharma GlaxoSmithKline plc will pay a $20 million civil penalty to settle charges that it violated the Foreign Corrupt Practices Act when China-based subsidiaries spent millions of dollars on pay-to-prescribe schemes for several years to pump up sales.… Continue Reading

Chinese police charge former GSK China chief Mark Reilly

Chinese police Wednesday charged the British former boss of GlaxoSmithKline’s China unit and two other company executives with corruption for bribing health officials and doctors.

A Ministry of Public Security official said in Beijing that Mark Reilly (pictured) and two Chinese executives, Zhang Guowei and Zhao Hongyan, offered bribes to hospital personnel and doctors to boost GSK’s sales.… Continue Reading

GSK confirms Jordan, Lebanon bribe probes

GlaxoSmithKline said it is investigating allegations of bribery in Jordan and Lebanon first reported by the media.

The UK-based pharma giant said in a statement Wednesday the probes are ongoing.

GSK said it has a “zero tolerance” for illegal behavior.… Continue Reading